Bleeding Disorders
Conference Coverage
Extended half-life clotting factors are safe, effective, and pricey
ORLANDO – Early experience with extended half-life clotting factor concentrates suggests these products are generally safe and effective, at least...
From the Journals
Rivaroxaban linked to more bleeding compared with dabigatran in elderly patients with nonvalvular AF
Rivaroxaban is associated with significantly more intra- and extracranial bleeding than is dabigatran in older patients who have nonvalvular...
Conference Coverage
Planning, education smooth transition to longer-acting clotting factors
Key clinical point: Transitioning patients to extended half-life clotting factor concentrates requires tailoring treatment to individual patients...
News
IVIg, corticosteroids appear comparable for ITP in pregnancy
Most pregnant women with a history of immune thrombocytopenia purpura need no treatment. For those who do, neonatal outcomes are comparable when...
Conference Coverage
Early intensive prophylaxis provides better QoL in hemophilia
Key clinical point: Early initiation of intensive bleeding prophylaxis was associated with significantly better health-related quality of life (...
Conference Coverage
Decision rule identifies unprovoked VTE patients who can halt anticoagulation
ROME – Half of women who have a first unprovoked venous thromboembolism can safely be spared lifelong anticoagulation through application of the...
News
FDA grants drug orphan designation for PNH
The US Food and Drug Administration (FDA) has granted orphan drug designation to Coversin as a treatment for paroxysmal nocturnal hemoglobinuria (...
News
Saline comparable to drug therapy for epistaxis in HHT
Photo courtesy of the University of Utah Health Sciences Center Results of a phase 2 study suggest a saline nose spray may be as effective as 3...
News
Bevacizumab no better than placebo for epistaxis in HHT
of nasal spray Bevacizumab nasal spray is no more effective than a placebo for reducing epistaxis caused by hereditary hemorrhagic telangiectasia...
News
ASH launches sickle cell coalition
The coalition aims to develop evidence-based treatment guidelines, educate clinicians, invest in research and clinical trials, and expand early...
Conference Coverage
Andexanet controlled factor Xa inhibitor–related bleeding
Key clinical point: Andexanet alfa achieved effective hemostasis in most patients with acute major bleeding on factor Xa inhibitors. Major finding...